{"id":"W2561629989","doi":"10.1182/blood.v112.11.3239.3239","title":"Safety and Efficacy of Subcutaneous (SC) Omacetaxine Mepesuccinate in Imatinib(IM)-Resistant Chronic Myeloid Leukemia (CML) Patients (pts) with the T315I Mutation – Results of An Ongoing Multicenter Phase II Study.","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Homoharringtonine; Imatinib; Internal medicine; Adverse effect; Dasatinib; Myeloid leukemia; Imatinib mesylate; Phases of clinical research; Gastroenterology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007040292,0.0004996741,0.0009651493,0.0001633469,0.0001876482,0.0004109042,0.0003464663,0.0005806933,0.001520976],"category_scores_gemma":[0.0007450919,0.0001952209,0.0005858364,0.0002746824,0.0003836822,0.0004820631,0.0001398646,0.001195567,0.0004160088],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003444024,"about_ca_system_score_gemma":0.0004574808,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004019649,"about_ca_topic_score_gemma":0.000748342,"domain_scores_codex":[0.9997677,0.0001102525,0.00002040326,0.00003914018,0.00002925284,0.00003329269],"domain_scores_gemma":[0.9994011,0.0001440074,0.000175839,0.00004776456,0.00002761924,0.0002036883],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5635842,0.03639222,0.02870374,0.0009277891,0.001359508,0.0006195463,0.0003953078,0.002997552,0.1443185,0.0002004721,0.003069586,0.2174316],"study_design_scores_gemma":[0.197208,0.7027206,0.08176368,0.00004703798,0.0006183831,0.001032231,0.0000759906,0.001987478,0.01159712,0.0001399714,0.002784286,0.00002527621],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978117,0.0009070053,0.0001753481,0.00008527753,0.00001345717,0.0002362605,0.0002552391,0.00001751637,0.0004981463],"genre_scores_gemma":[0.9976406,0.0005242491,0.0003233163,0.0001450653,0.00004738527,0.000215312,0.0007222085,0.000008246089,0.0003737035],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001520976,"threshold_uncertainty_score":0.005088151,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00963936395558686,"score_gpt":0.2564835968646108,"score_spread":0.2468442329090239,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}